JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257651

Human S100A11 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

S100A11 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.

View Alternative Names

S100C, MLN 70, Metastatic lymph node gene 70 protein, S100 calcium-binding protein A11, Protein S100-C, S100A11, Protein S100-A11, MLN70, Calgizzarin

2 Images
Sanger Sequencing - Human S100A11 knockout HeLa cell lysate (AB257651)
  • Sanger seq

Unknown

Sanger Sequencing - Human S100A11 knockout HeLa cell lysate (AB257651)

Homozygous : 1 bp insertion in exon2

Western blot - Human S100A11 knockout HeLa cell lysate (AB257651)
  • WB

Lab

Western blot - Human S100A11 knockout HeLa cell lysate (AB257651)

Lane 1 : Wild-type HeLa cell lysate 20 μg
Lane 2 : S100A11 knockout HeLa cell lysate 20 μg
Lane 3 : U-2 OS cell lysate 20 μg
Lane 4 : PC-3 cell lysate 20 μg
False colour image of Western blot : Anti-S100A11 antibody (ab187180) staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab187180 was shown to bind specifically to S100A11. A band was observed at 12 kDa in wild-type HeLa cell lysates with no signal observed at this size in S100A11 knockout cell line ab265085 (knockout cell lysate ab257651). To generate this image, wild-type and S100A11 knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

All lanes:

Anti-S100A11 antibody (<a href='/en-us/products/unavailable/s100a11-antibody-ab187180'>ab187180</a>) at 1/1000 dilution

Lane 1:

HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human S100A11 knockout HeLa cell lysate (ab257651) at 1/20000 dilution

Lane 3:

U-2 OS cell lysate at 20 µg

Lane 4:

PC-3 cell lysate at 20 µg

Secondary

Lanes 1 - 4:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/20000 dilution

Lanes 1 - 4:

Western blot - Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-irdye-680rd-preadsorbed-ab216776'>ab216776</a>) at 1/20000 dilution

Observed band size: 36 kDa

false

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Sanger seq": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257651-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human S100A11 knockout HeLa cell lysate", "number":"AB257651-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB257651-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
S100A11
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

S100A11 also known as Calgizzarin or MLN 70 is a calcium-binding protein of the S100 family. It has a molecular mass of approximately 11 kDa. S100A11 can be found in a wide range of tissues including skin placenta and heart. It exhibits the ability to bind calcium ions through its EF-hand motifs which influences its activity and stability. These calcium-binding domains make S100A11 an important regulator of various intracellular processes by responding to changes in calcium ion concentrations.
Biological function summary

The functions of S100A11 include involvement in cell proliferation differentiation and migration. S100A11 often operates as part of a protein complex facilitating these cellular processes by interacting with other signaling molecules. It can shuttle between the cytoplasm and nucleus influencing gene expression and cellular dynamics. S100A11 has also shown involvement in smooth muscle contraction and skin barrier function regulation.

Pathways

The activity involving S100A11 spans multiple biological pathways including the calcium signaling pathway and the epithelial cell signaling pathway. Through these pathways S100A11 maintains critical cellular homeostasis and function. In the calcium signaling pathway it interacts with proteins like annexins and calcyclin to modulate cellular responses to calcium influx. In epithelial cell signaling it affects pathways related to cell adhesion and communication integrating signals that dictate cell behavior in response to external stimuli.

S100A11 is relevant to cancer progression and inflammatory skin disorders. Its overexpression in various cancers such as bladder and prostate cancer suggests a role in tumor growth and metastasis. During the cancerous process S100A11 interacts with the p53 protein which impacts cell cycle regulation and survival. Additionally in inflammatory skin conditions like psoriasis S100A11 influences keratinocyte activity contributing to abnormal skin scaling and inflammation through interactions with filaggrin and keratin proteins.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com